Conformation-dependent recognition of HIV gp120 by designed ankyrin repeat proteins provides access to novel HIV entry inhibitors

Journal of Virology

Volumn 87, Issue 10, 2013, Pages 5868-5881

  Mann, Axel ^a   Friedrich, Nikolas ^a   Krarup, Anders ^a   Weber, Jacqueline ^a   Stiegeler, Emanuel ^a   Dreier, Birgit ^a   Pugach, Pavel ^b   Robbiani, Melissa ^b   Riedel, Tina ^a   Moehle, Kerstin ^a   Robinson, John A ^a   Rusert, Peter ^a   Plückthun, Andreas ^a   Trkola, Alexandra ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b POPULATION COUNCIL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; DESIGNED ANKYRIN REPEAT PROTEIN 3M2 A12; DESIGNED ANKYRIN REPEAT PROTEIN 3M3 A8; DESIGNED ANKYRIN REPEAT PROTEIN 3M3 B9; DESIGNED ANKYRIN REPEAT PROTEIN 3M3 D7; DESIGNED ANKYRIN REPEAT PROTEIN 3M3 F12; DESIGNED ANKYRIN REPEAT PROTEIN 5M3 D12; DESIGNED ANKYRIN REPEAT PROTEIN 6A2 A1; DESIGNED ANKYRIN REPEAT PROTEIN ANKF1 10; DESIGNED ANKYRIN REPEAT PROTEIN ANKF1 14; DESIGNED ANKYRIN REPEAT PROTEIN H3 1B3; EPITOPE; GLYCOPROTEIN GP 120; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1-79; MONOCLONAL ANTIBODY 19B; MONOCLONAL ANTIBODY 447 52D; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANTIGEN BINDING; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; BINDING SITE; CELL STRAIN HEK293; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG DESIGN; DRUG MECHANISM; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; IN VITRO STUDY; MACACA; MOLECULAR CLONING; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN MODIFICATION; SEQUENCE ANALYSIS; STRUCTURE ACTIVITY RELATION; VIRUS ENTRY; VIRUS INHIBITION; VIRUS NEUTRALIZATION; VIRUS PARTICLE; VIRUS SPIKE;

ANKYRIN REPEAT; HIV ENVELOPE PROTEIN GP120; HIV FUSION INHIBITORS; HUMANS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEINS;

EID: 84874020669     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00152-13     Document Type: Article

References (79)

1. Wilen CB, Tilton JC, and Doms RW. 2012. HIV: cell binding and entry. Cold Spring Harb. Perspect. Med. 2:a006866. doi:10.1101/cshperspect.a006866.
2. Lin PF, Blair W, Wang T, Spicer T, Guo Q, Zhou N, Gong YF, Wang HG, Rose R, Yamanaka G, Robinson B, Li CB, Fridell R, Deminie C, Demers G, Yang Z, Zadjura L, Meanwell N, Colonno R. 2003. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc. Natl. Acad. Sci. U. S. A. 100:11013-11018.
3. Gaertner H, Cerini F, Escola JM, Kuenzi G, Melotti A, Offord R, Rossitto-Borlat I, Nedellec R, Salkowitz J, Gorochov G, Mosier D, Hartley O. 2008. Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide. Proc. Natl. Acad. Sci. U. S. A. 105: 17706-17711.
4. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, Alldredge L, Hunter E, Lambert D, Bolognesi D, Matthews T, Johnson MR, Nowak MA, Shaw GM, Saag MS. 1998. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4:1302-1307.
5. Walker DK, Abel S, Comby P, Muirhead GJ, Nedderman AN, Smith DA. 2005. Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab. Dispos. 33:587-595.
6. Schief WR, Ban YE, Stamatatos L. 2009. Challenges for structure-based HIV vaccine design. Curr. Opin. HIV AIDS 4:431-440.
7. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, Hendrickson WA, Sodroski JG. 1998. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393:705-711.
8. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, Majeed S, Steenbeke TD, Venturi M, Chaiken I, Fung M, Katinger H, Parren PW, Robinson J, Van Ryk D, Wang L, Burton DR, Freire E, Wyatt R, Sodroski J, Hendrickson WA, Arthos J. 2002. HIV-1 evades antibodymediated neutralization through conformational masking of receptorbinding sites. Nature 420:678-682.
9. Starcich BR, Hahn BH, Shaw GM, McNeely PD, Modrow S, Wolf H, Parks ES, Parks WP, Josephs SF, Gallo RC, Wong-Staal F. 1986. Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell 45:637-648.
10. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM. 2003. Antibody neutralization and escape by HIV-1. Nature 422:307-312.
11. Go EP, Irungu J, Zhang Y, Dalpathado DS, Liao HX, Sutherland LL, Alam SM, Haynes BF, Desaire H. 2008. Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes' accessibility. J. Proteome Res. 7:1660-1674.
12. Parren PW, Moore JP, Burton DR, Sattentau QJ. 1999. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. AIDS 13(Suppl. A):S137-S162.
13. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393: 648-659.
14. Burton DR, Ahmed R, Barouch DH, Butera ST, Crotty S, Godzik A, Kaufmann DE, McElrath MJ, Nussenzweig MC, Pulendran B, Scanlan CN, Schief WR, Silvestri G, Streeck H, Walker BD, Walker LM, Ward AB, Wilson IA, Wyatt R. 2012. A blueprint for HIV vaccine discovery. Cell Host Microbe 12:396-407.
15. Binz HK, Stumpp MT, Forrer P, Amstutz P, Plückthun A. 2003. Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. J. Mol. Biol. 332:489-503.
16. Binz HK, Amstutz P, Kohl A, Stumpp MT, Briand C, Forrer P, Grütter MG, Plückthun A. 2004. High-affinity binders selected from designed ankyrin repeat protein libraries. Nat. Biotechnol. 22:575-582.
17. Zahnd C, Wyler E, Schwenk JM, Steiner D, Lawrence MC, McKern NM, Pecorari F, Ward CW, Joos TO, Plückthun A. 2007. A designed ankyrin repeat protein evolved to picomolar affinity to Her2. J. Mol. Biol. 369: 1015-1028.
18. Schweizer A, Rusert P, Berlinger L, Ruprecht CR, Mann A, Corthesy S, Turville SG, Aravantinou M, Fischer M, Robbiani M, Amstutz P, Trkola A. 2008. CD4-specific designed ankyrin repeat proteins are novel potent HIV entry inhibitors with unique characteristics. PLoS Pathog. 4:e1000109. doi:10.1371/journal.ppat.1000109.
19. Boersma YL, Plückthun A. 2011. DARPins and other repeat protein scaffolds: advances in engineering and applications. Curr. Opin. Biotechnol. 22:849-857.
20. Bork P. 1993. Hundreds of ankyrin-like repeats in functionally diverse proteins: mobile modules that cross phyla horizontally? Proteins 17:363-374.
21. Rusert P, Krarup A, Magnus C, Brandenberg OF, Weber J, Ehlert AK, Regoes RR, Günthard HF, Trkola A. 2011. Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies. J. Exp. Med. 208:1419-1433.
22. Barbas CF, III, Bjorling E, Chiodi F, Dunlop N, Cababa D, Jones TM, Zebedee SL, Persson MA, Nara PL, Norrby E, Burton DR. 1992.Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc. Natl. Acad. Sci. U. S. A. 89:9339-9343.
23. Parren PW, Gauduin MC, Koup RA, Poignard P, Fisicaro P, Burton DR, Sattentau QJ. 1997. Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design. Immunol. Lett. 57:105-112.
24. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong CH, Phogat S, Wrin T, Simek MD, Koff WC, Wilson IA, Burton DR, Poignard P. 2011. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477:466-470.
25. Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, Pietzsch J, Ott RG, Anthony RM, Zebroski H, Hurley A, Phogat A, Chakrabarti B, Li Y, Connors M, Pereyra F, Walker BD, Wardemann H, Ho D, Wyatt RT, Mascola JR, Ravetch JV, Nussenzweig MC. 2009. Broad diversity of neutralizing antibodies isolated from memory B cells in HIVinfected individuals. Nature 458:636-640.
26. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, Srinivasan K, Sodroski J, Moore JP, Katinger H. 1996. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70:1100-1108.
27. Thali M, Moore JP, Furman C, Charles M, Ho DD, Robinson J, Sodroski J. 1993. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J. Virol. 67:3978-3988.
28. Gorny MK, Conley AJ, Karwowska S, Buchbinder A, Xu JY, Emini EA, Koenig S, Zolla-Pazner S. 1992. Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J. Virol. 66:7538-7542.
29. Pantophlet R, Aguilar-Sino RO, Wrin T, Cavacini LA, Burton DR. 2007. Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis. Virology 364:441-453.
30. Stricher F, Huang CC, Descours A, Duquesnoy S, Combes O, Decker JM, Kwon YD, Lusso P, Shaw GM, Vita C, Kwong PD, Martin L. 2008. Combinatorial optimization of a CD4-mimetic miniprotein and cocrystal structures with HIV-1 gp120 envelope glycoprotein. J. Mol. Biol. 382: 510-524.
31. Riedel T, Ghasparian A, Moehle K, Rusert P, Trkola A, Robinson JA. 2011. Synthetic virus-like particles and conformationally constrained peptidomimetics in vaccine design. Chembiochem 12:2829-2836.
32. Haas J, Park EC, Seed B. 1996. Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Curr. Biol. 6:315-324.
33. Andre S, Seed B, Eberle J, Schraut W, Bultmann A, Haas J. 1998. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J. Virol. 72:1497-1503.
34. Barouch DH, Yang ZY, Kong WP, Korioth-Schmitz B, Sumida SM, Truitt DM, Kishko MG, Arthur JC, Miura A, Mascola JR, Letvin NL, Nabel GJ. 2005. A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J. Virol. 79:8828-8834.
35. Selvarajah S, Puffer B, Pantophlet R, Law M, Doms RW, Burton DR. 2005. Comparing antigenicity and immunogenicity of engineered gp120. J. Virol. 79:12148-12163.
36. Zahnd C, Amstutz P, Plückthun A. 2007. Ribosome display: selecting and evolving proteins in vitro that specifically bind to a target. Nat. Methods 4:269-279.
37. Dreier B, Plückthun A. 2011. Ribosome display: a technology for selecting and evolving proteins from large libraries. Methods Mol. Biol. 687: 283-306.
38. Dreier B, Plückthun A. 2012. Rapid selection of high-affinity binders using ribosome display. Methods Mol. Biol. 805:261-286.
39. Moulard M, Lortat-Jacob H, Mondor I, Roca G, Wyatt R, Sodroski J, Zhao L, Olson W, Kwong PD, Sattentau QJ. 2000. Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J. Virol. 74:1948-1960.
40. Vives RR, Imberty A, Sattentau QJ, Lortat-Jacob H. 2005. Heparan sulfate targets the HIV-1 envelope glycoprotein gp120 coreceptor binding site. J. Biol. Chem. 280:21353-21357.
41. Zaccolo M, Williams DM, Brown DM, Gherardi E. 1996. An approach to random mutagenesis of DNA using mixtures of triphosphate derivatives of nucleoside analogues. J. Mol. Biol. 255:589-603.
42. Zahnd C, Sarkar CA, Plückthun A. 2010. Computational analysis of off-rate selection experiments to optimize affinity maturation by directed evolution. Protein Eng. Des. Sel. 23:175-184.
43. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. 2011. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol. Biol. Evol. 28:2731-2739.
44. Jones DT, Taylor WR, Thornton JM. 1992. The rapid generation of mutation data matrices from protein sequences. Comput. Appl. Biosci. 8:275-282.
45. Kohl A, Binz HK, Forrer P, Stumpp MT, Plückthun A, Grütter MG. 2003. Designed to be stable: crystal structure of a consensus ankyrin repeat protein. Proc. Natl. Acad. Sci. U. S. A. 100:1700-1705.
46. Rusert P, Mann A, Huber M, von Wyl V, Günthard HF, Trkola A. 2009. Divergent effects of cell environment on HIV entry inhibitor activity. AIDS 23:1319-1327.
47. Adachi A, Koenig S, Gendelman HE, Daugherty D, Gattoni-Celli S, Fauci AS, Martin MA. 1987. Productive, persistent infection of human colorectal cell lines with human immunodeficiency virus. J. Virol. 61:209-213.
48. Koyanagi Y, Miles S, Mitsuyasu RT, Merrill JE, Vinters HV, Chen IS. 1987. Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science 236:819-822.
49. Cheng-Mayer C, Weiss C, Seto D, Levy JA. 1989. Isolates of human immunodeficiency virus type 1 from the brain may constitute a special group of the AIDS virus. Proc. Natl. Acad. Sci. U. S. A. 86:8575-8579.
50. Trkola A, Kuster H, Rusert P, von Wyl V, Leemann C, Weber R, Stiegler G, Katinger H, Joos B, Günthard HF. 2008. In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers. J. Virol. 82:1591-1599.
51. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, Voss G, Goepfert P, Gilbert P, Greene KM, Bilska M, Kothe DL, Salazar-Gonzalez JF, Wei X, Decker JM, Hahn BH, Montefiori DC. 2005. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79:10108-10125.
52. Pejchal R, Wilson IA. 2010. Structure-based vaccine design in HIV: blind men and the elephant? Curr. Pharm. Des. 16:3744-3753.
53. Kwon YD, Finzi A, Wu X, Dogo-Isonagie C, Lee LK, Moore LR, Schmidt SD, Stuckey J, Yang Y, Zhou T, Zhu J, Vicic DA, Debnath AK, Shapiro L, Bewley CA, Mascola JR, Sodroski JG, Kwong PD. 2012. Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. Proc. Natl. Acad. Sci. U. S. A. 109:5663-5668.
54. van Gils MJ, Bunnik EM, Boeser-Nunnink BD, Burger JA, Terlouw-Klein M, Verwer N, Schuitemaker H. 2011. Longer V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies. J. Virol. 85:6986-6995.
55. Olshevsky U, Helseth E, Furman C, Li J, Haseltine W, Sodroski J. 1990. Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding. J. Virol. 64:5701-5707.
56. Pantophlet R, Ollmann Saphire E, Poignard P, Parren PW, Wilson IA, Burton DR. 2003. Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J. Virol. 77:642-658.
57. Li Y, Migueles SA, Welcher B, Svehla K, Phogat A, Louder MK, Wu X, Shaw GM, Connors M, Wyatt RT, Mascola JR. 2007. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat. Med. 13: 1032-1034.
58. Xiang SH, Doka N, Choudhary RK, Sodroski J, Robinson JE. 2002. Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies. AIDS Res. Hum. Retroviruses 18:1207-1217.
59. Li Y, Svehla K, Louder MK, Wycuff D, Phogat S, Tang M, Migueles SA, Wu X, Phogat A, Shaw GM, Connors M, Hoxie J, Mascola JR, Wyatt R. 2009. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J. Virol. 83:1045-1059.
60. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905.
61. Stanfield RL, Gorny MK, Zolla-Pazner S, Wilson IA. 2006. Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity. J. Virol. 80:6093-6105.
62. Burke V, Williams C, Sukumaran M, Kim SS, Li H, Wang XH, Gorny MK, Zolla-Pazner S, Kong XP. 2009. Structural basis of the crossreactivity of genetically related human anti-HIV-1 mAbs: implications for design of V3-based immunogens. Structure 17:1538-1546.
63. Rosen O, Sharon M, Quadt-Akabayov SR, Anglister J. 2006. Molecular switch for alternative conformations of the HIV-1 V3 region: implications for phenotype conversion. Proc. Natl. Acad. Sci. U. S. A. 103:13950-13955.
64. Robinson JA. 2008. Beta-hairpin peptidomimetics: design, structures and biological activities. Acc. Chem. Res. 41:1278-1288.
65. Scott CF, Jr, Silver S, Profy AT, Putney SD, Langlois A, Weinhold K, Robinson JE. 1990. Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type IIIMN strain. Proc. Natl. Acad. Sci. U. S. A. 87:8597-8601.
66. Amstutz P, Binz HK, Parizek P, Stumpp MT, Kohl A, Grütter MG, Forrer P, Plückthun A. 2005. Intracellular kinase inhibitors selected from combinatorial libraries of designed ankyrin repeat proteins. J. Biol. Chem. 280:24715-24722.
67. Eggel A, Buschor P, Baumann MJ, Amstutz P, Stadler BM, Vogel M. 2011. Inhibition of ongoing allergic reactions using a novel anti-IgE DARPin-Fc fusion protein. Allergy 66:961-968.
68. Sennhauser G, Amstutz P, Briand C, Storchenegger O, Grütter MG. 2007. Drug export pathway of multidrug exporter AcrB revealed by DARPin inhibitors. PLoS Biol. 5:e7. doi:10.1371/journal.pbio.0050007.
69. North B, Lehmann A, and Dunbrack RL, Jr. 2011. A new clustering of antibody CDR loop conformations. J. Mol. Biol. 406:228-256.
70. McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, Khayat R, Louder R, Pejchal R, Sastry M, Dai K, O'Dell S, Patel N, Shahzad-ul Hussan S, Yang Y, Zhang B, Zhou T, Zhu J, Boyington JC, Chuang GY, Diwanji D, Georgiev I, Kwon YD, Lee D, Louder MK, Moquin S, Schmidt SD, Yang ZY, Bonsignori M, Crump JA, Kapiga SH, Sam NE, Haynes BF, Burton DR, Koff WC, Walker LM, Phogat S, Wyatt R, Orwenyo J, Wang LX, Arthos J, Bewley CA, Mascola JR, Nabel GJ, Schief WR, Ward AB, Wilson IA, Kwong PD. 2011. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480:336-343.
71. Pejchal R, Doores KJ, Walker LM, Khayat R, Huang PS, Wang SK, Stanfield RL, Julien JP, Ramos A, Crispin M, Depetris R, Katpally U, Marozsan A, Cupo A, Maloveste S, Liu Y, McBride R, Ito Y, Sanders RW, Ogohara C, Paulson JC, Feizi T, Scanlan CN, Wong CH, Moore JP, Olson WC, Ward AB, Poignard P, Schief WR, Burton DR, Wilson IA. 2011. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334:1097-1103.
72. Boersma YL, Chao G, Steiner D, Wittrup KD, Plückthun A. 2011. Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling. J. Biol. Chem. 286:41273-41285.
73. Moore PL, Gray ES, Sheward D, Madiga M, Ranchobe N, Lai Z, Honnen WJ, Nonyane M, Tumba N, Hermanus T, Sibeko S, Mlisana K, Abdool Karim SS, Williamson C, Pinter A, Morris L. 2011. Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. J. Virol. 85:3128-3141.
74. Krachmarov C, Lai Z, Honnen WJ, Salomon A, Gorny MK, Zolla-Pazner S, Robinson J, Pinter A. 2011. Characterization of structural features and diversity of variable-region determinants of related quaternary epitopes recognized by human and rhesus macaque monoclonal antibodies possessing unusually potent neutralizing activities. J. Virol. 85: 10730-10740.
75. Dreier B, Honegger A, Hess C, Nagy-Davidescu G, Mittl PR, Grütter MG, Belousova N, Mikheeva G, Krasnykh V, Plückthun A. 2013. Development of a generic adenovirus delivery system based on structureguided design of bispecific trimeric DARPin adapters. Proc. Natl. Acad. Sci. U. S. A. 110:E869-E877.
76. Mao Y, Wang L, Gu C, Herschhorn A, Xiang SH, Haim H, Yang X, Sodroski J. 2012. Subunit organization of the membrane-bound HIV-1 envelope glycoprotein trimer. Nat. Struct. Mol. Biol. 19:893-899.
77. Tran EE, Borgnia MJ, Kuybeda O, Schauder DM, Bartesaghi A, Frank GA, Sapiro G, Milne JL, Subramaniam S. 2012. Structural mechanism of trimeric HIV-1 envelope glycoprotein activation. PLoS Pathog. 8:e1002797. doi:10.1371/journal.ppat.1002797.
78. Harris A, Borgnia MJ, Shi D, Bartesaghi A, He H, Pejchal R, Kang YK, Depetris R, Marozsan AJ, Sanders RW, Klasse PJ, Milne JL, Wilson IA, Olson WC, Moore JP, Subramaniam S. 2011. Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. Proc. Natl. Acad. Sci. U. S. A. 108:11440-11445.
79. Sellhorn G, Kraft Z, Caldwell Z, Ellingson K, Mineart C, Seaman MS, Montefiori DC, Lagerquist E, Stamatatos L. 2012. Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins. J. Virol. 86:128-142.